De-repression of NFAT by palbociclib or another CDK4/6 inhibitor, trilaciclib led to T cell activation and synergized with immune checkpoint inhibitors in an organotypic tumor spheroid culture model and in syngeneic tumors in mice. Here, CDK4 is linked to neoplasm.